Chiromics and Bristol-Myers Squibb Company Form Drug Discovery Strategic Alliance

Published: Nov 09, 2012

PRINCETON, N.J.--(BUSINESS WIRE)--Chiromics LLC today announced a strategic research alliance with Bristol-Myers Squibb Company (NYSE:BMY) which includes grants of non-exclusive license for use of Chiromics’ chemical compound library, exclusive license to a proprietary chemical compound collection, and a screening collaboration to discover and optimize novel classes of small molecules against multiple therapeutic targets.

Back to news